Holen Sie sich die Stockscreener-App
23.07
4.72%
1.04
Handel nachbörslich:
23.05
-0.02
-0.09%
Schlusskurs vom Vortag:
$22.03
Offen:
$22.33
24-Stunden-Volumen:
449.64K
Relative Volume:
3.71
Marktkapitalisierung:
$1.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.28M
KGV:
-11.56
EPS:
-1.9957
Netto-Cashflow:
$-57.45M
1W Leistung:
+15.35%
1M Leistung:
+12.43%
6M Leistung:
+25.18%
1J Leistung:
+23.37%
1-Tages-Spanne:
$22.25
$23.99
1-Wochen-Bereich:
$19.70
$23.99
52-Wochen-Spanne:
$14.00
$23.99
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
23.07 | 1.27B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation - simplywall.st
Is Oculis Holding AG stock recession proofEarnings Growth Report & Smart Money Movement Alerts - ulpravda.ru
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis - Indian Pharma Post
Why Oculis Holding AG Equity Warrant stock could rally in 2025 - ulpravda.ru
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy - MSN
Can Oculis Holding AG Equity Warrant stock beat analyst upgradesJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
Will Oculis Holding AG stock maintain momentum in 2025Trade Exit Report & Expert Curated Trade Ideas - ulpravda.ru
IPO Launch: Why Oculis Holding AG stock is recommended by analystsWeekly Profit Report & Free Reliable Trade Execution Plans - ulpravda.ru
Can Oculis Holding AG (CR5) stock surprise with quarterly resultsMarket Movement Recap & Long-Term Capital Growth Ideas - ulpravda.ru
Why Oculis Holding AG Equity Warrant stock attracts global investorsCandlestick Trading Patterns & Low Risk Trading Plans - bollywoodhelpline.com
Weekly Earnings: Can Oculis Holding AG Equity Warrant stock beat analyst upgradesQuarterly Investment Review & Comprehensive Market Scan Reports - ulpravda.ru
Why Oculis Holding AG stock could benefit from AI revolutionJuly 2025 Snapshot & Comprehensive Market Scan Reports - ulpravda.ru
Will Oculis Holding AG Equity Warrant stock deliver consistent dividendsJuly 2025 Update & Long-Term Safe Investment Ideas - ulpravda.ru
Why Oculis Holding AG stock is recommended by analysts2025 Price Momentum & Low Risk High Reward Ideas - ulpravda.ru
OCSOculis Holding Latest Stock News & Market Updates - Stock Titan
Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline - MarketScreener
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyFibonacci Retracement Levels & Unlock Smart Investment Tactics That Work - ulpravda.ru
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference - The Manila Times
Oculis Holding AG Advances PIONEER Program with Breakthrough Therapy Designation for Privosegtor and Prepares for Upcoming J.P. Morgan Healthcare Conference Presentation - Quiver Quantitative
Experimental eye drugs target vision loss in diabetes and optic nerve disease - Stock Titan
FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis - Eyes On Eyecare
Should I hold or sell Oculis Holding AG Equity Warrant stock in 20252026 world cup usa national team qualification goalkeepers transition play odds analysis insights - ulpravda.ru
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2026 world cup usa national team qualification star players transition play knockout prediction guide - ulpravda.ru
What drives Oculis Holding AG stock priceDouble Top/Bottom Patterns & Free Stay Ahead With Picks - earlytimes.in
Oculis (NASDAQ:OCS) Shares Gap UpShould You Buy? - MarketBeat
Oculis gains on FDA breakthrough therapy status (OCS:NASDAQ) - Seeking Alpha
Oculis stock surges after FDA grants breakthrough therapy designation By Investing.com - Investing.com Nigeria
Oculis stock surges after FDA grants breakthrough therapy designation - Investing.com
Aug Rallies: Can Oculis Holding AG CR5 stock surprise with quarterly resultsEarnings Beat & Reliable Breakout Forecasts - moha.gov.vn
Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - MarketScreener
Oculis Holding Says FDA Granted Breakthrough Therapy Designation for Privosegtor - marketscreener.com
Oculis Holding AG's Privosegtor Receives Breakthrough Therapy Designation for Optic Neuritis Treatment - Quiver Quantitative
Oculis tilkynnir um að Matvæla- og lyfjastofnun - GlobeNewswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - MarketScreener
How Oculis Holding Ag (OCS) Affects Rotational Strategy Timing - Stock Traders Daily
Wall Street analysts predict a 106.04% upside in Oculis Holding AG (OCS): Here's what you should know - MSN
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6% - MarketBeat
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS‑05 and PIONEER Program Progress - simplywall.st
Oculis (NASDAQ:OCS) Shares Down 4.3%Time to Sell? - MarketBeat
Net current asset value per share of Oculis Holding AG – FWB:CR5 - TradingView — Track All Markets
Cash per share of Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING – NASDAQ:OCSAW - TradingView — Track All Markets
Why analysts upgrade Oculis Holding AG Equity Warrant stock2025 Buyback Activity & Safe Entry Zone Tips - Улправда
Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS) - simplywall.st
Is Oculis Holding AG (CR5) stock cheap vs fundamentalsQuarterly Market Summary & Daily Technical Forecast Reports - Улправда
Can Oculis Holding AG stock deliver surprise earnings beatMarket Activity Recap & AI Based Buy/Sell Signal Reports - Улправда
How Oculis Holding AG Equity Warrant stock reacts to inflationary pressuresMarket Rally & Low Risk Growth Stock Ideas - Улправда
Take Profit: How Oculis Holding AG Equity Warrant stock benefits from tech adoptionWeekly Market Outlook & Daily Technical Forecast Reports - Улправда
Oculis (NASDAQ:OCS) Given New $40.00 Price Target at Stifel Nicolaus - Defense World
Oculis (NASDAQ:OCS) Now Covered by JPMorgan Chase & Co. - Defense World
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):